The relatively limited therapeutic options for managing metastatic and late stage HCC [25,26,27,28] necessitates the discovery of reliable targetable or druggable disease-specific biomarkers such as COL1A1, and gives clinical and/or translational relevance to the findings of this present study. This evidence concerns the gene COL1A1 and hepatocellular carcinoma.